Could a diabetes drug curb heavy drinking in HIV patients?
NCT ID NCT07221214
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether semaglutide, a drug used for diabetes, can help adults with HIV reduce their alcohol intake and smoking, and lower their risk of heart disease. About 200 participants will take semaglutide or a placebo for 3 months and provide blood, stool, and saliva samples. The goal is to see if the drug can improve overall health in this group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can spit reveal how smoking fuels gum disease?
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia